→ Why has medical innovation in cardiovascular diseases stagnated even as other therapeutic areas have thrived? Novartis CEO Vas Narasimhan thinks a shift from broad-based development strategies to a more focused medicines approach is needed, and drug makers, regulators and payers all have a role to play.
In a column published in Fortune this week, Narasimhan argues that pharma companies need to be better at precision medicine in this field: categorizing patients, tracking biomarkers, and using more real world data. They can’t, however, do it alone; regulators must adopt their policies to recognize “scientifically robust subgroup data” for that to work. Lastly, he wrote, payers could make it easier for patients by implementing value-based reimbursement strategies. Given the case Novartis has been pitching for canakinumab, Narasimhan has a stake in pushing for all this: “There’s been much discussion on this topic, but the time to act is now.”
→ J&J $JNJ has received a $2.1 billion bid from serial buyout investor Platinum Equity, which wants to snatch up the pharma giant’s diabetes care company LifeScan. A major maker of blood glucose monitoring products, LifeScan brought in $1.5 billion in revenue for J&J in 2017. If Platinum takes over the operations, the company’s president Valerie Asbury would continue leading the business under new ownership, Platinum said in a statement. Last year, J&J said it was evaluating options for its diabetes care companies — specifically LifeScan, Animas Corp, and Calibra Medical — as sales have been falling since 2012. J&J has until June to accept Platinum’s offer.
→ Bavarian Nordic signed a $36 million alliance with the US Department of Defense to develop a prophylactic vaccine against the equine encephalitis virus — a rare mosquito-borne illness. With funding from the DoD, Bavarian Nordic will use its MVA-BN platform to develop a vaccine against various strains of the virus.
With contribution by John Carroll.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.Free Subscription